Andy Protter

Andy Protter has more than 35 years of pharmaceutical industry experience working on preclinical research and development projects involving proteins, peptides and small molecules. At Auransa, he is responsible for all research, discovery and preclinical development activities.

Before joining Auransa, Andy held various R&D and business development leadership roles at Medivation and Scios Inc. (acquired by Johnson & Johnson), where he won the Johnson Medal for his work on Natrecor, a product approved for decompensated congestive heart failure. While at Medivation, Andy was responsible for preclinical pharmacology and toxicology of Enzalutamide, a drug approved for advanced prostate cancer, and he participated in the in-licensing of the phase III PARPx inhibitor Talazoparib. He also led the first successful cloning of apoB, the primary protein on LDL, and has participated in work described in more than 84 published papers, four book chapters and 28 patents. Andy earned a Ph.D. in Biochemistry from the State University of New York at Stony Brook.